PMA device
Durolane
Bioventus, LLC · Acid, Hyaluronic, Intraarticular (MOZ, Class III) · First FDA decision Aug 29, 2017, newest Nov 29, 2020Knee osteoarthritis
Last checked: Nov 20, 2026Source: FDA, CMS, ClinicalTrials.gov, PubMed
FDA decisions
2
PMA pathway
Device trials
15
Naming "Durolane"
MAUDE reports
167
Brand "Durolane", since 2015
PubMed studies
27
Mentioning "Durolane"
AI summary across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, MAUDE and PubMed data on this page, plus web searches for payment facts.
Product review deck
A slide deck reviewing Durolane
About ten slides on the technology, clinical evidence, regulatory history and commercialization, built with AI from the data on this page and web research, with sources. Download it as PowerPoint to edit or as PDF to share.
- Executive summary and key facts
- Technology
- Clinical evidence and trials
- Regulatory history and safety
- Reimbursement, market and competition
- Risks, outlook and sources
AI-written from public data and may contain mistakes. Check each fact against its source before relying on it. Not investment, legal, reimbursement or medical advice.
FDA decisions
The newest 2 of 2 decisions filed under this name.
- DUROLANEPMA supplement
P170007-S007 · Decided Nov 29, 2020 · 89 days after receipt · Normal 180 Day Track
Device type: Acid, hyaluronic, intraarticular (MOZ) · Orthopedic Surgery
- DUROLANEPMA
P170007 · Decided Aug 29, 2017 · 180 days after receipt
Device type: Acid, hyaluronic, intraarticular (MOZ) · Orthopedic Surgery
Medicare coverage
National and local coverage documents whose titles match this device or its device type. Payment add-ons (NTAP, pass-through, TCET) and likely codes are covered in the summary above.
No Medicare coverage document has a title matching this device or device type. Many devices are paid under existing codes without one.
Clinical trials
Device studies on ClinicalTrials.gov that name "Durolane", any status and sponsor, newest update first.
- The Efficacy and Safety Study of 2107 Injection in Subjects With Mild to Moderate Knee OsteoarthritisPivotal-lookingNot yet recruiting
BioRegen Biomedical (Changzhou) Co., LtdNot on our public-company list
NCT07746843 · 286 participants (planned) · Start Sep 1, 2026 · Primary completion Jun 30, 2028
Device: 2107 Injection; DUROLANE® · For: Mild Knee Osteoarthritis; Moderate Knee Osteoarthritis
Sites: Krakow, Poland; Sabadell, Spain; Glasgow, United Kingdom
Allegro NV/SANot on our public-company list
NCT06839222 · 0 participants · Start May 2025 · Primary completion Nov 2026
Device: Hydrogel OA 2%; Hyaluronic Acid (Durolane) · For: Knee Osteoarthritis (Knee OA)
Sites: Antwerp, Belgium; Bruges, Belgium; Edegem, Belgium · 5 sites in all
Galderma R&DNot on our public-company list
NCT01265459 · 68 participants · Start Jan 2011 · Primary completion Sep 2011
Device: Durolane 3 ml, Durolane 4,5 ml, Durolane 6 ml · For: Knee Osteoarthritis
Sites: Malmö, Sweden; Stockholm, Sweden; Upplands Vasby, Sweden
12 more trials with a free account
Adverse event reports (MAUDE)
Reports received since 2015 naming the brand "Durolane", and for the whole product code for context.
This brand
167 reports: 26 malfunction, 127 injury, 11 death
Whole product code MOZ
4,975 reports: 669 malfunction, 3,945 injury, 278 death
Newest reports for this brand
- DUROLANEInjury
3009595577-2026-00004 · Received Oct 27, 2026
Device type: Acid, Hyaluronic, Intraarticular (MOZ)
Device problem as coded: Adverse Event Without Identified Device or Use Problem
Patient problem as coded: Pain; Reaction to Medicinal Component of Device; Swelling/ Edema
MW6004125 · Received Oct 16, 2026 · Event dated Sep 17, 2026
Device type: Acid, Hyaluronic, Intraarticular (MOZ)
Device problem as coded: Patient Device Interaction Problem
Patient problem as coded: Inflammation; Pain; Ambulation or Postural Difficulties; Swelling/ Edema
- DUROLANEInjury
3009595577-2026-00003 · Received Sep 11, 2026
Device type: Acid, Hyaluronic, Intraarticular (MOZ)
Device problem as coded: Use of Device Problem
Patient problem as coded: Rash
2 more reports with a free account
Recalls
From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.
No recall in FDA's data is linked to these FDA numbers.
Published research
The most relevant PubMed records for "Durolane"[tiab]. The summary above synthesizes these.
- Single Injection of Cross-Linked Hyaluronate in Knee Osteoarthritis: A 52-Week Double-Blind Randomized Controlled Trial.
Ko PY, Li CY, Li CL, et al. · Pharmaceutics · 2022
- Characterization of the visco-elastic properties of hyaluronic acid.
Lázaro B, Alonso P, Rodriguez A, et al. · Biorheology · 2018Comparative Study
- [Reduction of arthrosis associated knee pain through a single intra-articular injection of synthetic hyaluronic acid].
Krocker D, Matziolis G, Tuischer J, et al. · Z Rheumatol · 2006Clinical Trial, English Abstract
- Intra-articular Duration of Durolaneࡊ after Single Injection into the Rabbit Knee.
Edsman K, Hjelm R, Lärkner H, et al. · Cartilage · 2011
- Efficacy of a single ultrasound-guided injection for the treatment of hip osteoarthritis.
Atchia I, Kane D, Reed MR, et al. · Ann Rheum Dis · 2011Randomized Controlled Trial, Research Support, Non-U.S. Gov't
- Intraarticular Hyaluronic Acid Preparations for Knee Osteoarthritis: Are Some Better Than Others?
Webner D, Huang Y, Hummer CD · Cartilage · 2021Research Support, Non-U.S. Gov't, Review
- A Comprehensive Review of Viscosupplementation in Osteoarthritis of the Knee.
Peck J, Slovek A, Miro P, et al. · Orthop Rev (Pavia) · 2021Review
- Efficacy and Safety of Intra-Articular Cross-Linked Sodium Hyaluronate for the Treatment of Knee Osteoarthritis: A Prospective, Active-Controlled, Randomized, Parallel-Group, Double-Blind, Multicenter Study.
Blicharski T, ukasik P, Plebanski R, et al. · J Clin Med · 2023
- Two new intra-articular injections for knee osteoarthritis.
Med Lett Drugs Ther · 2018
- Foreign body giant cell reaction due to Durolane (hyaluronic acid derivative) injection - A case report.
Doddridge JR, Banner KA, Hunter NB, et al. · Skeletal Radiol · 2025Case Reports
- Comparison of two hyaluronic acid formulations for safety and efficacy (CHASE) study in knee osteoarthritis: a multicenter, randomized, double-blind, 26-week non-inferiority trial comparing Durolane to Artz.
Zhang H, Zhang K, Zhang X, et al. · Arthritis Res Ther · 2015Multicenter Study, Randomized Controlled Trial
- Cost-Effectiveness of Different Forms of Intra-Articular Injections for the Treatment of Osteoarthritis of the Knee.
Rosen J, Sancheti P, Fierlinger A, et al. · Adv Ther · 2016
Other devices of this type
Also filed under product code MOZ.
- EUFLEXXA (1% Sodium Hyaluronate)Ferring Pharmaceuticals, Inc. · PMA 2017
- Gel-One(R)Seikagaku Corp. · PMA 2016
- Supartz FxSeikagaku Corp. · PMA 2016
- SupartzSeikagaku Corp. · PMA 2015
- Orthovisc High Molecular Weight HyaluronanAnika Therapeutics, Inc. · PMA 2011
- MonoviscAnika Therapeutics, Inc. · PMA 2020
- HyalganFidia Farmaceutici S.P.A. · PMA 2008
- Orthovisc Sodium HyaluronateAnika Therapeutics, Inc. · PMA 2007
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.